Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M.
Kruit WH, et al. Among authors: van ojik hh.
Int J Cancer. 2005 Nov 20;117(4):596-604. doi: 10.1002/ijc.21264.
Int J Cancer. 2005.
PMID: 15945101
Clinical Trial.